Twitxy Saved

Yara Abdou, MD, MSCR

Verified account This account is verified. Learn more

@YAbdouMD

Breast Medical Oncologist | Clinical Trialist and Researcher @UNC_Lineberger | Views are my own.
Chapel Hill, NC med.unc.edu/medicine/oncol… Joined May 2024
633 Following 1K Followers 537 Posts

Latest posts 5

Yara Abdou, MD, MSCR Verified account @YAbdouMD
Can ctDNA help us detect molecular residual disease and guide personalized treatment in patients with high-risk TNBC?

Our @TheTBCRC PREDICT-RD trial is investigating MRD-guided treatment with datopotamab deruxtecan (Dato-DXd) in patients with persistent ctDNA after neoadjuvant therapy and surgery.

Now open at @UNC_Lineberger and @ONealCancerUAB

Opening soon at @UChicago, @MontefioreNYC @MayoCancerCare & @DukeCancer

Thank you @PRIMR_MED for highlighting our study and helping raise awareness!

🎥 Watch below!

#bcsm
PRIMR @PRIMR_MED 1d
New video! 📢

The PREDICT-RD trial studies whether MRD testing can catch early #breastcancer recurrence and guide personalized treatment for patients who still have TNBC remaining after surgery.

Watch:
primrmed.com/cancer-clinica…

@NateraGenetics @YAbdouMD @UNC_Lineberger
View quoted post on X
3 replies 12 reposts 25 likes 1.9K views View on X
Yara Abdou, MD, MSCR Verified account @YAbdouMD
Truly an honor to be part of this trailblazing group of investigators advancing breast cancer research and transforming patient care!

Here’s to 20 years of innovation and many more to come! 👏
Paolo Tarantino Verified account @PTarantinoMD 2d
Celebrating 20 years of @TheTBCRC!

A terrific community of investigators bringing innovation to patients and tackling important clinical questions often left unanswered by registrational trials.

An impressive track record, with the invaluable support of @SusanGKomen and @BCRFcure:

🔬 74 trials approved
👥 7,700+ participants enrolled
📚 72 peer-reviewed publications
🎤 140+ scientific presentations
💪And much more to come, including 4 oral presentations at #SABCS26!

Excited to join @MitchElliott18 as Social Media Co-Chair and help share the incredible research coming from this group!

👉 Follow @TheTBCRC to stay updated!
View quoted post on X
3 replies 4 reposts 27 likes 1.2K views View on X
Yara Abdou, MD, MSCR Verified account @YAbdouMD
As evidence continues to evolve, so does our approach to tailoring chemotherapy decisions.

We highlight key lessons from recent genomic trials, remaining uncertainties, and the importance of individualized, shared decision-making.

#bcsm @JCO_ASCO @UNC_Lineberger
Journal of Clinical Oncology Verified account @JCO_ASCO Nov 10
From TAILORx to OPTIMA: Evolving Evidence for Genomically Guided Chemotherapy in Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer. Co-authored by @YAbdouMD and @DrLisaCarey.

Read the full article. bit.ly/4yV3G9B
#BreastCancer #bcsm
View quoted post on X
0 replies 0 reposts 10 likes 530 views View on X
Yara Abdou, MD, MSCR Verified account @YAbdouMD
Excited to share our new @JAMAOnc paper on the rapidly evolving first-line treatment landscape for HER2+ metastatic breast cancer!

With more options than ever, the key question is: Who needs what, and how much treatment is enough?

jamanetwork.com/journals/jamao…

@OncoAlert #bcsm
@UNC_Lineberger @yuzongmd @DrLisaCarey
jamanetwork.com Evolving First-Line Treatment Strategies in ERBB2-Positive Metastatic Breast Cancer This narrative review explores expansions in the treatment landscape of ERBB2-positive metastatic breast cancer.
🚨 With more emerging 1L options than ever for HER2+ MBC, how should we choose?

Check out our new @JAMAOnc publication: Evolving First-Line Treatment Strategies in ERBB2-Positive Metastatic Breast Cancer

🔓jamanetwork.com/journals/jamao…

@DrLisaCarey @YAbdouMD

#BreastCancer #HER2
View quoted post on X
0 replies 14 reposts 60 likes 2.5K views View on X
Yara Abdou, MD, MSCR Verified account @YAbdouMD
Check out our new publication: “From TAILORx to OPTIMA, genomic assays continue to reshape chemotherapy decisions in HR+/HER2− breast cancer” @JCO_ASCO @DrLisaCarey

@UNC_Lineberger

ascopubs.org/doi/10.1200/JC…

Thanks for sharing our paper @DrRishabhOnco
ascopubs.org From TAILORx to OPTIMA: Evolving Evidence for Genomically Guided Chemotherapy in Hormone Receptor...
Dr Rishabh Jain Verified account @DrRishabhOnco Oct 31
🚨 Are we overtreating early breast cancer with chemotherapy?

A timely perspective in @JCO_ASCO revisits 4 landmark trials: MINDACT → TAILORx → RxPONDER → OPTIMA.

The evolution of genomic-guided chemotherapy in HR+/HER2− breast cancer is fascinating.

🔹 MINDACT | MammaPrint
High clinical risk ≠ automatic chemotherapy. Favorable genomic biology can support omission.

🔹 TAILORx | Oncotype DX
Most node-negative patients with RS 11–25 can avoid chemotherapy. Younger women remain an important exception.

🔹 RxPONDER | Oncotype DX
With 1–3 positive nodes and RS ≤25:
• Postmenopausal: No meaningful chemotherapy benefit.
• Premenopausal: Significant benefit persists.

🔹 OPTIMA | Prosigna (PAM50)
The next frontier!

✅ Included patients with up to 9 positive nodes.
✅ ROR ≤60 guided chemotherapy omission.
✅ ~2/3 avoided chemotherapy.
✅ Genomic-guided treatment was noninferior at 3.9 years’ median follow-up.

But here’s the BIG unanswered question:

Does chemotherapy benefit younger women because of its cytotoxic effects, or because it suppresses ovarian function?

OPTIMA mandated ovarian suppression in premenopausal participants and found no significant heterogeneity by menopausal status.

This is hypothesis-generating, NOT definitive proof.

🔬 Next to watch: OFSET (NRG-BR009) and OPTIMA-YOUNG.

💡 My takeaway: The future isn’t simply identifying who can skip chemotherapy. It’s determining whether optimized endocrine therapy can replace chemotherapy in selected younger women.

Excellent perspective by @YAbdouMD and Lisa Carey.

@myesmo @ESMO_open @OncoAlert

#BreastCancer #PrecisionOncology #ESMO26

Full paper link in comment below ⬇️
View quoted post on X